The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer

Yu Fujita, Shigehiro Yagishita, Keitaro Hagiwara, Yusuke Yoshioka, Nobuyoshi Kosaka, Fumitaka Takeshita, Tomohiro Fujiwara, Koji Tsuta, Hiroshi Nokihara, Tomohide Tamura, Hisao Asamura, Makoto Kawaishi, Kazuyoshi Kuwano, Takahiro Ochiya

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape. Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer (NSCLC), independent of immunoinhibitory signals. miR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo. Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis. Furthermore, we demonstrate that a miR-197 mimic sensitizes PD-L1 high drug-resistant cells to chemotherapy. These results indicate that the biological interaction between PD-L1 and chemoresistance occurs through the microRNA regulatory cascade. More importantly, expression levels of miR-197 are inversely correlated with PD-L1 expression (n = 177; P = 0.026) and are associated with worse overall survival (P = 0.015). Our discoveries suggest that the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.

Original languageEnglish
Pages (from-to)717-727
Number of pages11
JournalMolecular Therapy
Volume23
Issue number4
DOIs
Publication statusPublished - Apr 10 2015
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
Ligands
Biomarkers
Tumor Escape
bcl-2 Genes
Cyclin D1
Platinum
MicroRNAs
Neoplasms
Down-Regulation
Neoplasm Metastasis
Drug Therapy
Lung
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., ... Ochiya, T. (2015). The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Molecular Therapy, 23(4), 717-727. https://doi.org/10.1038/mt.2015.10

The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. / Fujita, Yu; Yagishita, Shigehiro; Hagiwara, Keitaro; Yoshioka, Yusuke; Kosaka, Nobuyoshi; Takeshita, Fumitaka; Fujiwara, Tomohiro; Tsuta, Koji; Nokihara, Hiroshi; Tamura, Tomohide; Asamura, Hisao; Kawaishi, Makoto; Kuwano, Kazuyoshi; Ochiya, Takahiro.

In: Molecular Therapy, Vol. 23, No. 4, 10.04.2015, p. 717-727.

Research output: Contribution to journalArticle

Fujita, Y, Yagishita, S, Hagiwara, K, Yoshioka, Y, Kosaka, N, Takeshita, F, Fujiwara, T, Tsuta, K, Nokihara, H, Tamura, T, Asamura, H, Kawaishi, M, Kuwano, K & Ochiya, T 2015, 'The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer', Molecular Therapy, vol. 23, no. 4, pp. 717-727. https://doi.org/10.1038/mt.2015.10
Fujita, Yu ; Yagishita, Shigehiro ; Hagiwara, Keitaro ; Yoshioka, Yusuke ; Kosaka, Nobuyoshi ; Takeshita, Fumitaka ; Fujiwara, Tomohiro ; Tsuta, Koji ; Nokihara, Hiroshi ; Tamura, Tomohide ; Asamura, Hisao ; Kawaishi, Makoto ; Kuwano, Kazuyoshi ; Ochiya, Takahiro. / The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. In: Molecular Therapy. 2015 ; Vol. 23, No. 4. pp. 717-727.
@article{a043b60f040e455cb3ed065c51918a86,
title = "The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer",
abstract = "Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape. Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer (NSCLC), independent of immunoinhibitory signals. miR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo. Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis. Furthermore, we demonstrate that a miR-197 mimic sensitizes PD-L1 high drug-resistant cells to chemotherapy. These results indicate that the biological interaction between PD-L1 and chemoresistance occurs through the microRNA regulatory cascade. More importantly, expression levels of miR-197 are inversely correlated with PD-L1 expression (n = 177; P = 0.026) and are associated with worse overall survival (P = 0.015). Our discoveries suggest that the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.",
author = "Yu Fujita and Shigehiro Yagishita and Keitaro Hagiwara and Yusuke Yoshioka and Nobuyoshi Kosaka and Fumitaka Takeshita and Tomohiro Fujiwara and Koji Tsuta and Hiroshi Nokihara and Tomohide Tamura and Hisao Asamura and Makoto Kawaishi and Kazuyoshi Kuwano and Takahiro Ochiya",
year = "2015",
month = "4",
day = "10",
doi = "10.1038/mt.2015.10",
language = "English",
volume = "23",
pages = "717--727",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer

AU - Fujita, Yu

AU - Yagishita, Shigehiro

AU - Hagiwara, Keitaro

AU - Yoshioka, Yusuke

AU - Kosaka, Nobuyoshi

AU - Takeshita, Fumitaka

AU - Fujiwara, Tomohiro

AU - Tsuta, Koji

AU - Nokihara, Hiroshi

AU - Tamura, Tomohide

AU - Asamura, Hisao

AU - Kawaishi, Makoto

AU - Kuwano, Kazuyoshi

AU - Ochiya, Takahiro

PY - 2015/4/10

Y1 - 2015/4/10

N2 - Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape. Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer (NSCLC), independent of immunoinhibitory signals. miR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo. Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis. Furthermore, we demonstrate that a miR-197 mimic sensitizes PD-L1 high drug-resistant cells to chemotherapy. These results indicate that the biological interaction between PD-L1 and chemoresistance occurs through the microRNA regulatory cascade. More importantly, expression levels of miR-197 are inversely correlated with PD-L1 expression (n = 177; P = 0.026) and are associated with worse overall survival (P = 0.015). Our discoveries suggest that the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.

AB - Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape. Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer (NSCLC), independent of immunoinhibitory signals. miR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo. Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis. Furthermore, we demonstrate that a miR-197 mimic sensitizes PD-L1 high drug-resistant cells to chemotherapy. These results indicate that the biological interaction between PD-L1 and chemoresistance occurs through the microRNA regulatory cascade. More importantly, expression levels of miR-197 are inversely correlated with PD-L1 expression (n = 177; P = 0.026) and are associated with worse overall survival (P = 0.015). Our discoveries suggest that the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84927005034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927005034&partnerID=8YFLogxK

U2 - 10.1038/mt.2015.10

DO - 10.1038/mt.2015.10

M3 - Article

C2 - 25597412

AN - SCOPUS:84927005034

VL - 23

SP - 717

EP - 727

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -